Your browser doesn't support javascript.
loading
Cohort study examining associations between ceramide levels and risk of multimorbidity among persons participating in the Mayo Clinic Biobank.
St Sauver, Jennifer L; LeBrasseur, Nathan K; Rocca, Walter A; Olson, Janet E; Bielinski, Suzette J; Sohn, Sunghwan; Weston, Susan A; McGree, Michaela E; Mielke, Michelle M.
Afiliación
  • St Sauver JL; Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA stsauver.jennifer@mayo.edu.
  • LeBrasseur NK; Robert and Arlene Kogod Center on Aging, Mayo Clinic, Rochester, Minnesota, USA.
  • Rocca WA; Department of Physical Medicine and Rehabilitation, Mayo Clinic, Rochester, Minnesota, USA.
  • Olson JE; Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
  • Bielinski SJ; Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
  • Sohn S; Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
  • Weston SA; Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
  • McGree ME; Department of Artificial Intelligence & Informatics, Mayo Clinic, Rochester, Minnesota, USA.
  • Mielke MM; Division of Clinical Trials and Biostatistics, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
BMJ Open ; 13(4): e069375, 2023 04 21.
Article en En | MEDLINE | ID: mdl-37085302
OBJECTIVE: Ceramides have been associated with several ageing-related conditions but have not been studied as a general biomarker of multimorbidity (MM). Therefore, we determined whether ceramide levels are associated with the rapid development of MM. DESIGN: Retrospective cohort study. SETTING: Mayo Clinic Biobank. PARTICIPANTS: 1809 persons in the Mayo Clinic Biobank ≥65 years without MM at the time of enrolment, and with ceramide levels assayed from stored plasma. PRIMARY OUTCOME MEASURE: Persons were followed for a median of 5.7 years through their medical records to identify new diagnoses of 20 chronic conditions. The number of new conditions was divided by the person-years of follow-up to calculate the rate of accumulation of new chronic conditions. RESULTS: Higher levels of C18:0 and C20:0 were associated with a more rapid rate of accumulation of chronic conditions (C18:0 z score RR: 1.30, 95% CI: 1.10 to 1.53; C20:0 z score RR: 1.26, 95% CI: 1.07 to 1.49). Higher C18:0 and C20:0 levels were also associated with an increased risk of hypertension and coronary artery disease. CONCLUSIONS: C18:0 and C20:0 were associated with an increased risk of cardiometabolic conditions. When combined with biomarkers specific to other diseases of ageing, these ceramides may be a useful component of a biomarker panel for predicting accelerated ageing.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Ceramidas / Multimorbilidad Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: BMJ Open Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Ceramidas / Multimorbilidad Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: BMJ Open Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido